Genmab A/S
CSE:GMAB
Genmab A/S
Other Receivables
Genmab A/S
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Other Receivables
kr101m
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other Receivables
kr97.4m
|
CAGR 3-Years
38%
|
CAGR 5-Years
45%
|
CAGR 10-Years
26%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Receivables
€11.2m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
26%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Receivables
kr40.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Other Receivables
kr9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Saniona AB
STO:SANION
|
Other Receivables
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Other Receivables?
Other Receivables
101m
DKK
Based on the financial report for Dec 31, 2024, Genmab A/S's Other Receivables amounts to 101m DKK.
What is Genmab A/S's Other Receivables growth rate?
Other Receivables CAGR 3Y
48%
The average annual Other Receivables growth rates for Genmab A/S have been 48% over the past three years .
You don't have any saved screeners yet